KREBSBIO

Krebs Biochemicals & Industries Share Price

₹98.70 -5.15 (-4.96%)

22 Jan, 2025 12:36

SIP TrendupStart SIP in KREBSBIO

Start SIP

Performance

  • Low
  • ₹99
  • High
  • ₹105
  • 52 Week Low
  • ₹60
  • 52 Week High
  • ₹129
  • Open Price₹105
  • Previous Close₹104
  • Volume10,525

Investment Returns

  • Over 1 Month + 1.38%
  • Over 3 Month + 20.37%
  • Over 6 Month -10.98%
  • Over 1 Year + 33.56%
SIP Lightning

Smart Investing Starts Here Start SIP with Krebs Biochemicals & Industries for Steady Growth!

Invest Now

Krebs Biochemicals & Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -9.8
  • PEG Ratio
  • 5.8
  • Market Cap Cr
  • 213
  • P/B Ratio
  • -1.8
  • Average True Range
  • 5.08
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.43
  • RSI
  • 59.47
  • MFI
  • 72.7

Krebs Biochemicals & Industries Financials

Krebs Biochemicals & Industries Technicals

EMA & SMA

Current Price
₹98.70
-5.15 (-4.96%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹96.09
  • 50 Day
  • ₹95.63
  • 100 Day
  • ₹92.09
  • 200 Day
  • ₹87.02

Resistance and Support

102.28 Pivot Speed
  • R3 110.27
  • R2 107.08
  • R1 105.47
  • S1 100.67
  • S2 97.48
  • S3 95.87

What's your outlook on Krebs Biochemicals & Industries?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Krebs Biocs.& Inds. has an operating revenue of Rs. 50.69 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of -39% needs improvement, ROE of 0% is poor and needs improvement. NULL The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 18% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -18% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 73 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Krebs Biochemicals & Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-04 Quarterly Results & Others To Consider Other business matters.
2024-11-11 Quarterly Results & Other To Consider Other business matters.
2024-08-07 Quarterly Results
2024-05-21 Audited Results
2024-02-12 Quarterly Results

Krebs Biochemicals & Industries F&O

Krebs Biochemicals & Industries Shareholding Pattern

72.74%
0.5%
20.02%
6.74%

About Krebs Biochemicals & Industries

  • NSE Symbol
  • KREBSBIO
  • BSE Symbol
  • 524518
  • Managing Director & CEO
  • Mr. Jitendra Shah
  • ISIN
  • INE268B01013

Similar Stocks to Krebs Biochemicals & Industries

Krebs Biochemicals & Industries FAQs

Krebs Biochemicals & Industries share price is ₹98 As on 22 January, 2025 | 12:22

The Market Cap of Krebs Biochemicals & Industries is ₹212.8 Cr As on 22 January, 2025 | 12:22

The P/E ratio of Krebs Biochemicals & Industries is -9.8 As on 22 January, 2025 | 12:22

The PB ratio of Krebs Biochemicals & Industries is -1.8 As on 22 January, 2025 | 12:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23